233 related articles for article (PubMed ID: 26708105)
1. Targeting Translation Control with p70 S6 Kinase 1 Inhibitors to Reverse Phenotypes in Fragile X Syndrome Mice.
Bhattacharya A; Mamcarz M; Mullins C; Choudhury A; Boyle RG; Smith DG; Walker DW; Klann E
Neuropsychopharmacology; 2016 Jul; 41(8):1991-2000. PubMed ID: 26708105
[TBL] [Abstract][Full Text] [Related]
2. Genetic removal of p70 S6 kinase 1 corrects molecular, synaptic, and behavioral phenotypes in fragile X syndrome mice.
Bhattacharya A; Kaphzan H; Alvarez-Dieppa AC; Murphy JP; Pierre P; Klann E
Neuron; 2012 Oct; 76(2):325-37. PubMed ID: 23083736
[TBL] [Abstract][Full Text] [Related]
3. Genetic removal of p70 S6K1 corrects coding sequence length-dependent alterations in mRNA translation in fragile X syndrome mice.
Aryal S; Longo F; Klann E
Proc Natl Acad Sci U S A; 2021 May; 118(18):. PubMed ID: 33906942
[TBL] [Abstract][Full Text] [Related]
4. Fragile X-like behaviors and abnormal cortical dendritic spines in cytoplasmic FMR1-interacting protein 2-mutant mice.
Han K; Chen H; Gennarino VA; Richman R; Lu HC; Zoghbi HY
Hum Mol Genet; 2015 Apr; 24(7):1813-23. PubMed ID: 25432536
[TBL] [Abstract][Full Text] [Related]
5. Isoform-selective phosphoinositide 3-kinase inhibition ameliorates a broad range of fragile X syndrome-associated deficits in a mouse model.
Gross C; Banerjee A; Tiwari D; Longo F; White AR; Allen AG; Schroeder-Carter LM; Krzeski JC; Elsayed NA; Puckett R; Klann E; Rivero RA; Gourley SL; Bassell GJ
Neuropsychopharmacology; 2019 Jan; 44(2):324-333. PubMed ID: 30061744
[TBL] [Abstract][Full Text] [Related]
6. Characterization of PF-4708671, a novel and highly specific inhibitor of p70 ribosomal S6 kinase (S6K1).
Pearce LR; Alton GR; Richter DT; Kath JC; Lingardo L; Chapman J; Hwang C; Alessi DR
Biochem J; 2010 Oct; 431(2):245-55. PubMed ID: 20704563
[TBL] [Abstract][Full Text] [Related]
7. Transcriptome signature analysis repurposes trifluoperazine for the treatment of fragile X syndrome in mouse model.
Ding Q; Sethna F; Wu XT; Miao Z; Chen P; Zhang Y; Xiao H; Feng W; Feng Y; Li X; Wang H
Commun Biol; 2020 Mar; 3(1):127. PubMed ID: 32179850
[TBL] [Abstract][Full Text] [Related]
8. Rescue of fragile X syndrome phenotypes in Fmr1 KO mice by the small-molecule PAK inhibitor FRAX486.
Dolan BM; Duron SG; Campbell DA; Vollrath B; Shankaranarayana Rao BS; Ko HY; Lin GG; Govindarajan A; Choi SY; Tonegawa S
Proc Natl Acad Sci U S A; 2013 Apr; 110(14):5671-6. PubMed ID: 23509247
[TBL] [Abstract][Full Text] [Related]
9. p70 S6K1 nuclear localization depends on its mTOR-mediated phosphorylation at T389, but not on its kinase activity towards S6.
Rosner M; Schipany K; Hengstschläger M
Amino Acids; 2012 Jun; 42(6):2251-6. PubMed ID: 21710263
[TBL] [Abstract][Full Text] [Related]
10. Altered mTOR signaling and enhanced CYFIP2 expression levels in subjects with fragile X syndrome.
Hoeffer CA; Sanchez E; Hagerman RJ; Mu Y; Nguyen DV; Wong H; Whelan AM; Zukin RS; Klann E; Tassone F
Genes Brain Behav; 2012 Apr; 11(3):332-41. PubMed ID: 22268788
[TBL] [Abstract][Full Text] [Related]
11. Molecular and cellular aspects of mental retardation in the Fragile X syndrome: from gene mutation/s to spine dysmorphogenesis.
De Rubeis S; Fernández E; Buzzi A; Di Marino D; Bagni C
Adv Exp Med Biol; 2012; 970():517-51. PubMed ID: 22351071
[TBL] [Abstract][Full Text] [Related]
12. Pharmacogenetic inhibition of eIF4E-dependent Mmp9 mRNA translation reverses fragile X syndrome-like phenotypes.
Gkogkas CG; Khoutorsky A; Cao R; Jafarnejad SM; Prager-Khoutorsky M; Giannakas N; Kaminari A; Fragkouli A; Nader K; Price TJ; Konicek BW; Graff JR; Tzinia AK; Lacaille JC; Sonenberg N
Cell Rep; 2014 Dec; 9(5):1742-1755. PubMed ID: 25466251
[TBL] [Abstract][Full Text] [Related]
13. Genetic deletion of regulator of G-protein signaling 4 (RGS4) rescues a subset of fragile X related phenotypes in the FMR1 knockout mouse.
Pacey LK; Doss L; Cifelli C; van der Kooy D; Heximer SP; Hampson DR
Mol Cell Neurosci; 2011 Mar; 46(3):563-72. PubMed ID: 21215802
[TBL] [Abstract][Full Text] [Related]
14. R-Baclofen Reverses a Social Behavior Deficit and Elevated Protein Synthesis in a Mouse Model of Fragile X Syndrome.
Qin M; Huang T; Kader M; Krych L; Xia Z; Burlin T; Zeidler Z; Zhao T; Smith CB
Int J Neuropsychopharmacol; 2015 Mar; 18(9):. PubMed ID: 25820841
[TBL] [Abstract][Full Text] [Related]
15. Mechanism-based treatments in neurodevelopmental disorders: fragile X syndrome.
Berry-Kravis E
Pediatr Neurol; 2014 Apr; 50(4):297-302. PubMed ID: 24518745
[TBL] [Abstract][Full Text] [Related]
16. Bryostatin-1 restores hippocampal synapses and spatial learning and memory in adult fragile x mice.
Sun MK; Hongpaisan J; Lim CS; Alkon DL
J Pharmacol Exp Ther; 2014 Jun; 349(3):393-401. PubMed ID: 24659806
[TBL] [Abstract][Full Text] [Related]
17. N-terminal variant Asp14Asn of the human p70 S6 Kinase 1 enhances translational signaling causing different effects in developing and mature neuronal cells.
Venkatasubramani JP; Subramanyam P; Pal R; Reddy BK; Srinivasan DJ; Chattarji S; Iossifov I; Klann E; Bhattacharya A
Neurobiol Learn Mem; 2020 May; 171():107203. PubMed ID: 32147585
[TBL] [Abstract][Full Text] [Related]
18. Multiple Behavior Phenotypes of the Fragile-X Syndrome Mouse Model Respond to Chronic Inhibition of Phosphodiesterase-4D (PDE4D).
Gurney ME; Cogram P; Deacon RM; Rex C; Tranfaglia M
Sci Rep; 2017 Nov; 7(1):14653. PubMed ID: 29116166
[TBL] [Abstract][Full Text] [Related]
19. Differential translation and fragile X syndrome.
Vanderklish PW; Edelman GM
Genes Brain Behav; 2005 Aug; 4(6):360-84. PubMed ID: 16098135
[TBL] [Abstract][Full Text] [Related]
20. A new tool to dissect the function of p70 S6 kinase.
Bilanges B; Vanhaesebroeck B
Biochem J; 2010 Oct; 431(2):e1-3. PubMed ID: 20874709
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
